Key Points
- CEO Sean Duffy sold 21,572 Omada Health shares at an average price of $23.62, generating approximately $509,531. He retains 411,861 shares, with the sale reducing his direct ownership by 4.98%.
- Omada Health reported quarterly EPS of $0.08, beating estimates by $0.10, while revenue of $87.83 million exceeded the $80.93 million consensus forecast.
- Analysts maintain a generally positive outlook, with 11 Buy ratings, two Holds and one Sell; the stock has a “Moderate Buy” consensus rating and a $26.50 average price target.
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CEO Sean Duffy sold 21,572 shares of Omada Health stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.62, for a total transaction of $509,530.64. Following the completion of the transaction, the chief executive officer directly owned 411,861 shares in the company, valued at approximately $9,728,156.82. The trade was a 4.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Omada Health Stock Performance
OMDA opened at $22.29 on Friday. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92. The stock has a market capitalization of $1.36 billion, a PE ratio of 445.80 and a beta of 1.86. The stock's 50 day moving average price is $22.66 and its 200-day moving average price is $17.54.
Omada Health (NASDAQ:OMDA - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.10. The company had revenue of $87.83 million during the quarter, compared to analysts' expectations of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. Research analysts forecast that Omada Health, Inc. will post 0.09 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on OMDA. Wall Street Zen raised shares of Omada Health from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of Omada Health in a research report on Friday, May 8th. BTIG Research boosted their price objective on shares of Omada Health from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Barclays upped their price objective on shares of Omada Health from $20.00 to $25.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Finally, Evercore reaffirmed an "outperform" rating and set a $20.00 target price on shares of Omada Health in a research note on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $26.50.
View Our Latest Stock Analysis on Omada Health
Institutional Investors Weigh In On Omada Health
Several hedge funds have recently added to or reduced their stakes in OMDA. Raymond James Financial Inc. bought a new position in shares of Omada Health during the second quarter valued at $32,000. Bellevue Group AG boosted its stake in Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company's stock worth $5,567,000 after purchasing an additional 1,791 shares in the last quarter. Quarry LP purchased a new stake in Omada Health during the 4th quarter valued at about $29,000. Barclays PLC grew its position in Omada Health by 14.6% during the 4th quarter. Barclays PLC now owns 14,850 shares of the company's stock valued at $234,000 after purchasing an additional 1,888 shares during the last quarter. Finally, Versant Capital Management Inc increased its stake in Omada Health by 319.3% during the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company's stock valued at $66,000 after purchasing an additional 2,283 shares in the last quarter.
Omada Health Company Profile
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
